This Tamgiblimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Sotevtamab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Lesabelimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

Proceeds will be used to advance the company's AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide July 21, 2026 -- Karoo Health, a cardiovascular technology company building an operating system supporting cardiac care, today announced the closing of a $16.2 million Series A financing round co-led by 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, LLC, SpringRock Ventures, Hyde Park Angels (HP

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,[1] and no currently approved therapies for the disease which is associated with rapid decline in kidney function and high mortality r

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson. AtaiBeckley’s lead candidate is BPL-003, a fast-acting intranasal formulation of the psychedelic substance 5-MeO-DMT. The substance, which is found in some plants and animals, stimulates the serotonin system that regulates mood. A phase 2b trial linked BPL-003 to statistically significant improve

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025. Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (o

SYNT-101 was well tolerated across all doses with no related GI adverse events, no serious adverse events, and no discontinuations Data confirm SYNT-101's intended mechanism of nutrient redirection, with reduced glucose absorption and favorable changes in satiety hormones after a single dose Additional data from the multiple ascending dose arm of the trial in obese patients is expected later this year Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with the help of a $315 million series D . The round was led by Ally Bridge Group and Alpha Wave, with returning support from the investment arms of Sanofi and Eli Lilly and new funders like Bain Capital Life Sciences. The series D has its origins at January’s J.P. Morgan Healthcare Conference, where radiotherapy wa

First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling July 16, 2026 -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the Unite